Maddipati Lab retweeted
Conventional therapies often fail in metastatic pancreatic cancer.
@MaddipatiLab @utswcancer reviews tumor-stroma interactions that shape metastatic progression in PDAC and highlight potential stage- and site-specific therapeutic opportunities for intervention: jci.org/articles/view/191943
Maddipati Lab retweeted
How does the location of a tumor influence #healthoutcomes? Check out @UTSWInternalMed researcher and #NIHHighRisk New Innovator Awardee Dr. Ravikanth Maddipati and his work to better understand #cancer. @UTSWNews utsouthwestern.edu/newsroom/…
Maddipati Lab retweeted
Early-stage investigators proposed innovative high-impact research ideas for the @NIHDirector’s New Innovator Award. See the projects the awardees will pursue: commonfund.nih.gov/newinnova… #NIHHighRisk
ALT Collage of photos of all the 2023 NIH Director's New Innovator Awardees
Excited to be one of the NIH New Innovator Award recipients! It is an honor and privilege to be in the company of so many innovative young scientists.
Looking for good post-docs to help carry the project forward!
xitter.cf/NIH_CommonFund/status/…
How does the location of a tumor influence #healthoutcomes? Check out @UTSWInternalMed researcher and #NIHHighRisk New Innovator Awardee Dr. Ravikanth Maddipati and his work to better understand #cancer. @UTSWNews utsouthwestern.edu/newsroom/…
Maddipati Lab retweeted
Katalin Karikó and Drew Weissman – awarded the 2023 #NobelPrize in Physiology or Medicine – discovered that base-modified mRNA can be used to block activation of inflammatory reactions and increase protein production when mRNA is delivered to cells.
Maddipati Lab retweeted
"This work has opened the door for a decade’s worth of research." -@timofran1
@umichmedicine & @GiftofLifeMich project shows PanIN lesions more common than previously thought, opening new pathway to understanding progression of pancreatic cancer. ⬇️⬇️⬇️
medicine.umich.edu/dept/surg…
Maddipati Lab retweeted
Pleiotrophin drives a prometastatic immune niche in #BreastCancer, say Debolina Ganguly @debog93, Rolf Brekken @brekkenlab et al @utswcancer @UTSWNews: bit.ly/3IRSdB9
@gilbertzmurimwa @FaValdesMora @dgallegoortega
#TumorImmunology #metastasis
Maddipati Lab retweeted
Excited to share our latest work highlighting the role of cell competition in shaping metastatic latency and relapse @CD_AACR !! A collaborative effort with @PayalKapur5 @JBrugarolas and @brekkenlab
@ElizSMcKenna - Appreciate all the support !!
Now online in @CD_AACR: Cell Competition Shapes Metastatic Latency and Relapse @KangsanKim_UTSW @MalladiLab @UTSW_Pathology @UTSWCancerBio @utswcancer @UTSWNews aacrjournals.org/cancerdisco…
Maddipati Lab retweeted
@aguilera_md @NiuSanford @drdavidpalma @Dr_AliHosni @TAMERMR @ldawsonmd @BobTimmermanMD
A series of SABR ttt PDAC oligomets (OPanc) (1-5 mets) published in Red Journal. Retro, small n & selection bias limiting, but SABR doubled OS with less time on CTH.
authors.elsevier.com/c/1fgzw…
Maddipati Lab retweeted
ICYMI: Final version of the @CD_AACR paper on T cell trajectories in pancreatic cancer is now online. Magnum opus from the @MDAndersonNews #PancreaticCancer #Moonshot team. Single cell RNAseq & TCRseq on 80,000 T cells, treasure trove for mining targets!
aacrjournals.org/cancerdisco… – at Houston, TX
Maddipati Lab retweeted
If you are interested in apCAFs in PDA give this paper from Huocong Huang a read. @utswcancer @UTSWCancerBio @UTSW_Surgery He had wonderful help from @TurleyLabGNE Mesothelial cell-derived antigen-presenting cancer-associated fibrobla... sciencedirect.com/science/ar…
Maddipati Lab retweeted
New paper resulting from a large collaborative effort btwn brekken/minna/fu/li labs @UTSWNews, @utswcancer. Lead author is another outstanding @UTSWCancerBio trainee. cell.com/cell-reports-medici…
Maddipati Lab retweeted
Our latest publication together with @SchneiderG_Dr lab in @EmboMolMed: Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems
embopress.org/doi/full/10.15…
@MaxReichertMD @sfb1321 @TU_Muenchen
1/4
Check out our paper on the drivers of metastatic heterogeneity in pancreatic cancer, finally out in Print @CD_AACR.
From the February issue: #MYC levels regulate #metastatic heterogeneity in pancreatic adenocarcinoma by @MaddipatiLab, Ben Stanger et al. bit.ly/3HvYcHV
@utswcancer @PennMedicine @PennCancer
Part 5: Similar analysis in a large cohort of paired human primary PDAC tumors and metastasis provided further evidence that MYC can function as a driver of metastatic heterogeneity, independent of its role in primary tumor growth.